PAR-24-162: Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)
Closed
This grant is closed. A newer notice from the same program is open now: Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed) (PAR-25-068). Status: Due dates in the notice, expires November 16, 2027. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on January 7, 2025.
From the official notice on Grants.gov, last changed March 19, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR21
- Clinical trialsNot allowed
- Funded byNIDDK
- Median yearly award$440,688
- Typical project length2 years
- R21, Exploratory/Developmental Research Grant. Early, exploratory ideas that may not have preliminary data yet, usually for up to two years. Other open R21 notices.
Projects funded under PAR-24-162 were run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-24-162 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-25-068 | January 8, 2025 | Due dates in the notice, expires November 16, 2027 | Open |
Key dates
| Posted | March 18, 2024 |
|---|---|
| Deadline | January 7, 2025 |
| Archived by Grants.gov | February 12, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Notice of Funding Opportunity (NOFO) invites applications for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently outlined by the NIH Office of AIDS Research (OAR) in NOT-20-018, UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding, scientific priorities. Potential topics could address multiple overarching priorities. These include elucidation of unique pathophysiological mechanisms contributing to HIV comorbidities, coinfections, and complications (CCCs) affecting organs, tissues, and processes within the mission of the NIDDK. Likewise, interrogations into biological mechanisms underlying HIV reservoirs in NIDDK-relevant tissues are important for developing strategies for long-term viral suppression or eradication. Finally, health-impeding social determinants of health may affect CCCs or viral reservoirs within NIDDK's mission through multiple pathways.
Funded under PAR-24-162 so far
NIH funded 2 projects under PAR-24-162 in fiscal 2025, at 2 institutions. The median yearly award was $440,688.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Investigation of the Role of MicroRNAs in Adipose Tissue from People Infected with HIV Who Develop Type 2 Diabetes | University of California, San Francisco | 2025 | $451,000 |
| Utilizing the ex vivo rectal explant challenge model to evaluate HIV-1 Transmitted/Founder replication and inflammation within human gut mucosal tissue | Emory University | 2025 | $430,375 |
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before
From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded $9.6 billion across 7,877 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 273 | $345 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 187 | $272 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 209 | $238 million |
| The Washington University | Missouri | 187 | $227 million |
| The Regents of the University of California, San Francisco | California | 176 | $208 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PAR-25-068, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-24-162 still open?
No. It closed on January 7, 2025. A newer notice is open: PAR-25-068, due dates in the notice, expires November 16, 2027.
Who can apply for Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)?
Closed January 7, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-24-162?
NIH RePORTER lists 2 projects funded under PAR-24-162 in fiscal 2025, at 2 institutions. The most were at University of California, San Francisco, Emory University.
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.
Similar open grants
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
- Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
- Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)